NCT06107686

A Study of YL202 in Selected Patients With Advanced Solid Tumors

A Multicenter, Open-Label, Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of YL202 in Selected Patients With Advanced Solid Tumors

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in the following selected patients with advanced solid tumors.

Detailed description

This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in the advanced NSCLC/BC/HNSCC/colorectal cancer/HER2-positive gastric cancer/cervical cancer/ovarian cancer and etc.

Conditions

• NSCLC
• Breast Cancer
• HNSCC
• Locally Advanced or Metastatic Solid Tumors

Interventions

Type	Name	Description
DRUG	YL202 should be intravenously infused	For each patient, YL202 should be intravenously infused over 60±10 min.

Timeline

• Start date: 2023-12-15
• Primary completion: 2026-11-01
• Completion: 2028-11-01
• First posted: 2023-10-30
• Last updated: 2025-11-26

Locations

82 sites across 1 country: China

Regulatory

• FDA-regulated drug study